Study of Multiple Doses of Danicopan in Healthy Participants
Study Identifier:
ACH471-002
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: Danicopan
- Drug: Placebo
Date
May 2016 - Jan 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 25 - 55 Years
Requirements Information
Sex
Female & Male
Age
25 - 55 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: Danicopan
- Drug: Placebo
Date
May 2016 - Jan 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 25 - 55 Years years
Requirements Information
Protocol Summary
This was a multiple ascending dose, randomized, double-blind study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of danicopan in healthy participants. Four different doses (75 milligrams \[mg\], 200 mg, 500 mg, 800 mg) and dose-matched placebo were administered under fasted conditions.
Trial Locations
Location
Status
Location
Clinical Trial Site
Auckland, New Zealand
Status
N/A